VRX Share Price

Open 9.39 Change Price %
High 9.49 1 Day -0.13 -1.39
Low 9.20 1 Week 0.65 7.56
Close 9.25 1 Month -1.78 -16.14
Volume 9062943 1 Year -24.11 -72.27
52 Week High 38.50
52 Week Low 8.31
VRX Important Levels
Resistance 2 9.52
Resistance 1 9.41
Pivot 9.31
Support 1 9.09
Support 2 8.98
NYSE USA Most Active Stocks
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
SE 40.68 -0.78%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
BAC 23.34 -1.31%
BAC 23.34 -1.31%
BAC 23.34 -1.31%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
FNP 35.24 12.02%
FNP 35.24 12.02%
AAN 35.94 11.93%
AAN 35.94 11.93%
IVC 14.70 10.94%
IVC 14.70 10.94%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Valeant Pharmaceuticals International, Inc. (NYSE: VRX)

VRX Technical Analysis 5
As on 28th Apr 2017 VRX Share Price closed @ 9.25 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 19.09 & Strong Sell for SHORT-TERM with Stoploss of 11.81 we also expect STOCK to react on Following IMPORTANT LEVELS.
VRX Target for May
1st Target up-side 10.75
2nd Target up-side 11.81
3rd Target up-side 12.86
1st Target down-side 7.75
2nd Target down-side 6.69
3rd Target down-side 5.64
VRX Other Details
Segment EQ
Market Capital 16095334400.00
Sector Healthcare
Industry Drug Delivery
Offical website http://www.valeant.com
VRX Address
VRX
2150 St. Elz
Laval, QC H7L 4A8
Canada
Phone: 514-744-6792
Fax: 514-744-6272
VRX Latest News
Objective Review Of Valeant   Seeking Alpha   - 29th Apr 17
Valeant Pharmaceuticals Intl Inc (VRX) Stock Still Looks Toxic   Investorplace.com   - 27th Apr 17
It's Time To Talk About Valeant   Seeking Alpha   - 27th Apr 17
Valeant Pharmaceuticals Intl Inc's (VRX) Bausch + Lomb Announces 510(k ...   Smarter Analyst   - 26th Apr 17
Valeant Can Beat Guidance   Seeking Alpha   - 26th Apr 17
Valeant Is Unfairly Undervalued II   Seeking Alpha   - 24th Apr 17
Valeant Pharmaceuticals Intl Inc (VRX) Is a Dead Drugmaker Walking   Investorplace.com   - 21st Apr 17
3 Stocks to Watch on Friday: Visa Inc (V), Valeant Pharmaceuticals Intl Inc ...   Investorplace.com   - 21st Apr 17
Valeant: Heading To Penny Stock Status?   Seeking Alpha   - 20th Apr 17
Valeant: Collapse Imminent   Seeking Alpha   - 19th Apr 17
Interactive Technical Analysis Chart Valeant Pharmaceuticals International, Inc. ( VRX NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Valeant Pharmaceuticals International, Inc.
VRX Business Profile
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.